• Explore /
  • Poster
  • / Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Abstract Video & Slides Poster

Authors

null

D. Ross Camidge

University of Colorado Cancer Center, Aurora, CO

D. Ross Camidge , Jair Bar , Hidehito Horinouchi , Jonathan W. Goldman , Fedor Vladimirovich Moiseenko , Elena Filippova , Irfan Cicin , Penelope Ann Bradbury , Nathalie Daaboul , Pascale Tomasini , Tudor-Eliade Ciuleanu , David Planchard , Mor Moskovitz , Nicolas Girard , Janet Yikai Jin , Martin Dunbar , Ellen Bolotin , Jim Looman , Christine Ratajczak , Shun Lu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03539536

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9016)

DOI

10.1200/JCO.2022.40.16_suppl.9016

Abstract #

9016

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Pingli Wang

First Author: Mingfang Zhao

First Author: Julien Mazieres

First Author: Rosario García Campelo